Intensity Therapeutics Common Stock Market Value
| INTS Stock | 0.43 0.01 2.26% |
| Symbol | Intensity |
Intensity Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intensity Therapeutics. If investors know Intensity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intensity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Intensity Therapeutics is measured differently than its book value, which is the value of Intensity that is recorded on the company's balance sheet. Investors also form their own opinion of Intensity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intensity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intensity Therapeutics' market value can be influenced by many factors that don't directly affect Intensity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intensity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intensity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intensity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Intensity Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Intensity Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Intensity Therapeutics.
| 10/16/2025 |
| 01/14/2026 |
If you would invest 0.00 in Intensity Therapeutics on October 16, 2025 and sell it all today you would earn a total of 0.00 from holding Intensity Therapeutics Common or generate 0.0% return on investment in Intensity Therapeutics over 90 days. Intensity Therapeutics is related to or competes with Iterum Therapeutics, Rallybio Corp, IBio Common, Pluri, Boundless Bio, Plus Therapeutics, and NextCure. Intensity Therapeutics is entity of United States More
Intensity Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Intensity Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Intensity Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 11.84 | |||
| Information Ratio | 0.0884 | |||
| Maximum Drawdown | 433.59 | |||
| Value At Risk | (14.04) | |||
| Potential Upside | 12.2 |
Intensity Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Intensity Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Intensity Therapeutics' standard deviation. In reality, there are many statistical measures that can use Intensity Therapeutics historical prices to predict the future Intensity Therapeutics' volatility.| Risk Adjusted Performance | 0.0774 | |||
| Jensen Alpha | 4.4 | |||
| Total Risk Alpha | (1.00) | |||
| Sortino Ratio | 0.3658 | |||
| Treynor Ratio | 40.82 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Intensity Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intensity Therapeutics Backtested Returns
Intensity Therapeutics is out of control given 3 months investment horizon. Intensity Therapeutics holds Efficiency (Sharpe) Ratio of 0.1, which attests that the entity had a 0.1 % return per unit of risk over the last 3 months. We were able to interpolate and analyze data for twenty-nine different technical indicators, which can help you to evaluate if expected returns of 5.11% are justified by taking the suggested risk. Use Intensity Therapeutics Common Downside Deviation of 11.84, risk adjusted performance of 0.0774, and Market Risk Adjusted Performance of 40.83 to evaluate company specific risk that cannot be diversified away. Intensity Therapeutics holds a performance score of 7 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 0.11, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Intensity Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Intensity Therapeutics is expected to be smaller as well. Use Intensity Therapeutics Common downside variance, as well as the relationship between the daily balance of power and period momentum indicator , to analyze future returns on Intensity Therapeutics Common.
Auto-correlation | -0.31 |
Poor reverse predictability
Intensity Therapeutics Common has poor reverse predictability. Overlapping area represents the amount of predictability between Intensity Therapeutics time series from 16th of October 2025 to 30th of November 2025 and 30th of November 2025 to 14th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Intensity Therapeutics price movement. The serial correlation of -0.31 indicates that nearly 31.0% of current Intensity Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.31 | |
| Spearman Rank Test | 0.21 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Intensity Therapeutics lagged returns against current returns
Autocorrelation, which is Intensity Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Intensity Therapeutics' stock expected returns. We can calculate the autocorrelation of Intensity Therapeutics returns to help us make a trade decision. For example, suppose you find that Intensity Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Intensity Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Intensity Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Intensity Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Intensity Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Intensity Therapeutics Lagged Returns
When evaluating Intensity Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Intensity Therapeutics stock have on its future price. Intensity Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Intensity Therapeutics autocorrelation shows the relationship between Intensity Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Intensity Therapeutics Common.
Regressed Prices |
| Timeline |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Intensity Stock Analysis
When running Intensity Therapeutics' price analysis, check to measure Intensity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intensity Therapeutics is operating at the current time. Most of Intensity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intensity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intensity Therapeutics' price. Additionally, you may evaluate how the addition of Intensity Therapeutics to your portfolios can decrease your overall portfolio volatility.